Eli Lilly and Company (LLY) Stake Held by BigSur Wealth Management LLC
BigSur Wealth Management LLC held its stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,187 shares of the company’s stock at the end of the second quarter. BigSur Wealth Management LLC’s holdings in Eli Lilly and were worth $344,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Shelton Capital Management bought a new position in shares of Eli Lilly and in the second quarter valued at approximately $827,000. Prudential PLC raised its stake in shares of Eli Lilly and by 37.1% in the second quarter. Prudential PLC now owns 157,453 shares of the company’s stock valued at $12,958,000 after acquiring an additional 42,579 shares during the last quarter. Williams Jones & Associates LLC raised its stake in shares of Eli Lilly and by 9.9% in the second quarter. Williams Jones & Associates LLC now owns 11,850 shares of the company’s stock valued at $975,000 after acquiring an additional 1,070 shares during the last quarter. Logan Capital Management Inc. raised its stake in shares of Eli Lilly and by 0.8% in the second quarter. Logan Capital Management Inc. now owns 28,279 shares of the company’s stock valued at $2,327,000 after acquiring an additional 229 shares during the last quarter. Finally, AHL Partners LLP raised its stake in shares of Eli Lilly and by 127.4% in the second quarter. AHL Partners LLP now owns 67,347 shares of the company’s stock valued at $5,543,000 after acquiring an additional 37,725 shares during the last quarter. Institutional investors own 76.61% of the company’s stock.
A number of analysts recently weighed in on the stock. Berenberg Bank reissued a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Morgan Stanley raised their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday. Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a report on Wednesday, July 26th. BMO Capital Markets reissued an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Wednesday, July 26th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $89.97.
Eli Lilly and Company (NYSE:LLY) opened at $83.51 on Wednesday. Eli Lilly and Company has a fifty-two week low of $64.18 and a fifty-two week high of $89.09. The stock has a market cap of $91,589.09, a price-to-earnings ratio of 20.34, a PEG ratio of 1.84 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the business earned $0.88 EPS. The firm’s revenue was up 9.0% on a year-over-year basis. sell-side analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.49%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock valued at $64,837,441 in the last three months. 0.20% of the stock is owned by company insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.